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Bevacizumab Application Delays Epithelial Healing in
Rabbit Cornea
Tae-im Kim, Jae Lim Chung, Jin Pyo Hong, Kyung Min, Kyoung Yul Seo, and
Eung Kweon Kim
PURPOSE. Vascular endothelial growth factor (VEGF) is essential
for neovascularization, but the use of anti-VEGF therapies to
inhibit neovascularization may influence epithelial wound heal-
ing. Here, the effects of bevacizumab on corneal epithelial
wound healing time in rabbit models, cell proliferation, and
expression of integrins in human corneal epithelial and fibro-
blast cells were evaluated.
METHODS. To compare epithelial wound healing times, epithe-
lial defect sizes were measured after application of bevaci-
zumab topical eye drops at 0, 0.5, 1.0, 1.5, 2.5, or 5 mg/mL,
twice daily, to mechanically debrided epithelia of rabbit cor-
neas. The cellular covering of wounded areas and expression
of Ki67 were assessed after scrape injuries in cultures of human
corneal epithelial and fibroblast cells. Expression of cell surface
integrins and collagens was measured using plates coated with
mouse monoclonal antibodies against human adhesion mole-
cules, and relevant mRNA levels were assessed by reverse-
transcription–polymerase chain reaction (RT-PCR).
RESULTS. The application of bevacizumab topical eye drops at
1.0, 1.5, 2.5, or 5 mg/mL delayed rabbit corneal epithelial
healing. Cell cultures growing under high concentrations of
bevacizumab showed delay in the proliferation of corneal ep-
ithelial and fibroblast cells. Surface expression of mRNA en-
coding integrins and collagens were decreased by 1.5 mg/mL
of bevacizumab.
CONCLUSIONS. Bevacizumab delayed corneal epithelial wound
healing and inhibited integrin expression. When bevacizumab
is used to reduce the development of new corneal vessels,
slight delays in epithelial wound healing are possible and cel-
lular proliferation is to be expected. (Invest Ophthalmol Vis
Sci. 2009;50:4653–4659) DOI:10.1167/iovs.08-2805
The normal human cornea is avascular, a situation main-tained by expression of anti-angiogenic factors. Inflamma-
tory and angiogenic stimuli allow vascular invasion when the
balance between such factors is tilted toward angiogenesis.1
Wound healing is composed of several overlapping phases and
includes the induction of acute inflammation, rapid prolifera-
tion of reparative cells, and formation of permanent scars.2 In
the complex microenvironment of a healing corneal wound, in
which multiple growth factors are found, vascular endothelial
growth factor (VEGF) has an important role.3 Several mecha-
nisms of pathologic neovascularization (NV) have been de-
scribed in wound healing. These processes involve the actions
of basic fibroblast growth factor (bFGF),4 prostaglandin,5 in-
terleukin (IL)-2 and IL-8,6 platelet-derived growth factor
(PDGF),7 and VEGF.8
VEGF is essential for other forms of wound- and inflamma-
tion-related neovascularization, but use of anti-VEGF therapies
for NV inhibition requires caution because the efficiency of
wound healing may be affected.9
Bevacizumab (Avastin; Genentech, San Francisco, CA) is a
recombinant humanized monoclonal immunoglobulin G1 anti-
body directed against VEGF.10 This antibody binds and deacti-
vates VEGF, which can result in inhibition of abnormal blood
vessel formation and decreased vascular permeability. Since mid-
2005, off-label use of bevacizumab has been reported in ocular
systems and the drug has shown promising short-term results in
the treatment of intraocular neovascular conditions.11,12
Systemic administration of bevacizumab results in a low
incidence of hypertension and thrombosis,13 but several re-
ports have suggested that small doses delivered topically do
not cause serious adverse effects.14–17 However, one group
reported corneal epithelial change in NV patients after topical
application of bevacizumab.18 Such application resulted not
only in vascular suppression but also caused spontaneous loss
of epithelial integrity and progressive stromal thinning.
In this study, we evaluated the effects of bevacizumab on
corneal wound healing time, cell growth, and expression of
Ki67 in scratch assays on the levels of cell surface integrins and
collagen, and expression of integrin mRNAs in human corneal
epithelial and fibroblast cells.
MATERIALS AND METHODS
In Vivo Rabbit Model of Corneal Epithelial
Wound Closure
New Zealand White rabbits, weighing 2 kg and housed in the animal
facilities of Yonsei University, were given rabbit chow and water ad
libitum and were cared for in accordance with the ARVO Statement for
the Use of Animals in Ophthalmic and Vision Research. The experi-
mental protocol was approved by the Institutional Animal Care and
Use Committee of Yonsei University Medical Center.
Twenty rabbits were anesthetized using ketamine (30 mg/kg of
body weight, intramuscularly) and xylazine (6 mg/kg, intramuscularly),
and proparacaine hydrochloride 0.5% (w/v) (Alcaine; Alcon, Fort
Worth, TX) was applied topically. The corneal epithelium was abraded
after a 30 second application of 20% (v/v) ethanol using a #15 surgical
blade (Bard-Parker; BD Surgical Systems, Franklin Lakes, NJ) on the
central portion of the cornea that had been demarcated with an 8.0
mm trephine.16 Ofloxacin eye ointment was applied once a day and
phosphate buffered saline (PBS) containing 0, 0.5, 1.0, or 1.5 mg/mL
bevacizumab was applied twice daily after suturing. Corneal epithelial
defects were stained with fluorescein and photographed every day
after wounding until epithelial defects were completely closed.
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To determine the area of corneal neovascularization, the pixels cov-
ering the vascularized corneal portion were measured on digitized pho-
tographs using Image J 1.31v software (kindly provided by Wayne Ras-
band of the Research Services Branch, National Institute of Mental Health,
Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html). The pho-
tographs were evaluated by two investigators. Differences in epithelial
defect areas were compared using Kruskal-Wallis tests. Commercial soft-
ware (MedCalc for Windows, version 7.6.0.0; MedCalc Software, Mari-
akerke, Belgium) was used for statistical analysis.
Culture of Corneal Epithelial and Fibroblast Cells
Telomerase (hTERT)-immortalized human corneal fibroblast cells17
were cultured with Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% (v/v) fetal calf serum (Gibco-BRL), 1% (w/v)
glutamate, and 1% (w/v) penicillin-streptomycin at 37°C under 5%
(v/v) CO2, in six-well tissue culture plates. Telomerase-immortalized
human corneal epithelial cells18 were grown in KGM-2 medium (Clo-
netics-BioWhittaker Inc., Walkersville, MD) supplemented with 200
U/mL penicillin, 200 g/mL streptomycin, and 0.5 g/mL amphoteri-
cin B (BioWhittaker) at 37°C under 5% (v/v) CO2, also in six-well tissue
culture plates.
Scratch Assay of Corneal Epithelial and Fibroblast
Cells and Ki67 Staining
Each cell line was cultured with supplemented media for 2 days and
monolayers in culture plates were wounded using a small scalpel.
Injured cells were cultured with 0, 1.0, 2.5, or 5.0 mg/mL bevacizumab
FIGURE 1. A rabbit cornea stained with fluorescein to measure the size of epithelial defects after mechanical debridement. Corneal epithelium
regenerated by day 3 in the control and 0.5 mg/mL bevacizumab groups. In animals treated with bevacizumab concentrations of 1.0 mg/mL and
above, delayed epithelial closure (days 4 to 5 after debridement) was evident.
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in the cell culture media for 24 hours. Cells were photographed using
a microscope 24 hours after wounding. Each experiment was repeated
three times. To determine the distance between the leading edges of
growing cells, the pixels were counted on digitized photographs using
Image J 1.31v software.
Corneal epithelial and fibroblast cells were cultured in two-well cham-
ber slides and underwent scratch assay and were treated with 0, 1.0, 2.5,
or 5.0 mg/mL bevacizumab for 24 hours. For Ki67 immunostaining, cells
were fixed with 2% paraformaldehyde (PFA, Wako) and permeabilized
with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO). The cells were
treated with rabbit polyclonal to Ki67-proliferation marker (Abcam, Cam-
bridge, MA). The cells were then treated with donkey anti-rabbit IgG
antibody (Alexa Fluor 594; Invitrogen, Carlsbad, CA).
Identification of Cell Surface Integrin  and 
Groups, and Types I and IV Collagen
To identify cell surface integrins and collagen, we used three different
assay kits (Alpha Integrin-Mediated Cell Adhesion Array Kit, Beta Inte-
grin-Mediated Cell Adhesion Array Kit, and CytoMatrix Cell Adhesion
Strips Human Collagen Type I and IV kit; Chemicon, Temecula, CA), in
which 96-well plates were coated with mouse monoclonal antibodies
against human adhesion molecules. The plates were used to capture
cells expressing specific surface adhesion molecules. Corneal epithelial
cells and fibroblasts exposed to 0 or 1.5 mg/mL bevacizumab for 24
hours were prepared as single cell suspensions using non-enzymatic
dissociation buffer (PBS with 2 to 5 mM EDTA). After adjusting the cell
density to 1  105 to 1  107 cells/mL with assay buffer, the mixture
was incubated at 37°C under 5% (v/v) CO2 for 45 minutes After several
washes with PBS, cell staining solution (100 L/well) was added and
incubated for 5 minutes. After several washes with PBS, extraction
buffer (100 L/well) was added and the suspension rotated on an
orbital shaker for 5 to 10 minutes. Reaction intensities were measured
at 570 nm (VERSAmax; Molecular Devices, Sunnyvale, CA). Experi-
ments were performed in triplicate. Differences between groups were
compared using the Mann–Whitney U test. Statistical analysis software
(SPSS version 12.0; SPSS, Chicago, IL) was used.
FIGURE 2. Sizes of epithelial defects
measured with Image J (software de-
veloped by Wayne Rasband, National
Institutes of Health, Bethesda, MD;
available at http://rsb.info.nih.gov/ij/
index.html). Statistically significant
epithelial defect size differences
were observed on day 3 and day 4
after debridement. *Statistically sig-
nificant between groups (Kruskal-
Wallis test).
FIGURE 3. Corneal epithelial cells growing and Ki-67 expression after wounding with a small scalpel. (A) Twenty-four hours later, the control
group and 1 mg/mL bevacizumab treatment group showed covering of the wounded area by proliferating cells. As the concentration of
bevacizumab increased, the proliferation of corneal epithelial cells was progressively delayed until 24 hours after injury. (B) The expression of Ki-67
positive cell was decreased with increasing bevacizumab concentration. (C) The distance between the leading edge of the growing cell was
measured by Image J 1.31v software. Statistically significant differences were observed in the bevacizumab-treated groups. Student-Newman-Keuls
test was used for all pairwise comparisons
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Reverse-Transcriptase–Polymerase Chain
Reaction Analysis of Integrin 2, 3, 5, 1, and
2, and Fibronectin mRNA Expression
Corneal epithelial cells and fibroblasts exposed to 0 or 1.5 mg/mL
bevacizumab for 24 hours were prepared for mRNA extraction. RNA
concentration and purity was determined spectrophotometrically
(Gene Quant II; Pharmacia Biotech, Cambridge, UK). Total RNA was
converted into cDNA using a premix kit (One-Step RT-PCR Pre-Mix Kit;
iNtRON, Daejeon, Korea). To measure integrin 1 transcription, an
mRNA aliquot was incubated in a thermal controller (Model TPC-100;
MJ Research, Watertown, MA) for 1 cycle of reverse transcription at
45°C for 30 minutes and denaturation at 94°C for 5 minutes, followed
by 33 cycles of denaturation at 94°C for 1 minute, annealing at 55°C for
1 minute, extension at 72°C for 1 minute, and a final extension at 72°C
for 5 minutes The primers used were 5-GCT GCT GTG CAT TAG ATA
TTA G-3 and 5-CTG TAA CTT CTG GTG AAA TCC T-3. Integrin 2
transcription was measured as above but the annealing temperature
was 57°C for 1 minute The primers used were 5-TAC GTGCGA GGC
AAT GAC CTA-3 and 5-TTT GGG GGT GCA GGA TGA AGC T-3.
Integrin 5 transcription was measured identically to the integrin 1
procedure described above. The primers used were 5-ACT AGG AAA
TCC ATT CAC AGT TC-3 and 5-GCA TAG TTA GTG TTC TTT GTT
GG-3. Integrin 1 transcription was measured identically to the inte-
grin 1 procedure described above. The primers used were 5-GTG
GTT GCT GGA ATT GTT CTT ATT-3 and 5-TTT TCC CTC ATA CTT
CGG ATT GAC-3. Integrin 2 transcription was measured in exactly
the same manner. The primers used were 5-TAG GAG CAC TTG GTG
AAG AC-3 and 5-AGA CTG ATG TCC TGA CTT GC-3. RT-PCR prod-
ucts were analyzed by electrophoresis in 1% (w/v) agarose gel. Ampli-
fied products were viewed using an image-documentation system (Im-
ageMaster VDS; Pharmacia Biotech Inc., Uppsala, Sweden). -actin
levels were used to normalize expression levels of each mRNA. Gels
were photographed and DNA band densities quantitated using a quan-
titative imaging system (Fluor-S MultiImager; Bio-Rad, Hercules, CA).
Experiments were performed three times.
RESULTS
Delayed Corneal Epithelial Wound Closure
by Bevacizumab
In rabbits receiving eyedrops with 0 or 0.5 mg/mL bevaci-
zumab, corneal epithelium regenerated by day 3 after mechan-
ical debridement. However, in animals receiving eyedrops
with 1.5, 2.5, or 5.0 mg/mL bevacizumab, delayed epithelial
closure was noted, and wounds did not heal until day 4 or day
5 after debridement (Fig. 1). Also, two corneas in the 1.5
mg/mL bevacizumab-treated group and three corneas in the
2.5 and 5.0 mg/mL-treated animals showed detachment of
epithelial layers and spontaneous increases in epithelial defect
size during wound healing. This indicated that high concentra-
tions of bevacizumab induced not only delayed epithelial re-
generation but also weakened the adhesion strength between
the corneal epithelium and the damaged stromal bed. The sizes
of measured epithelial defects were compared. Statistically
significant epithelial defect size differences were observed on
day 3 and day 4 after debridement (Fig. 2).
Delayed Covering of Wounded Area of Corneal
Epithelial Cells and Fibroblasts and Reduced
Expression of Ki67 by Bevacizumab
Twenty-four hours after creating wounds using a small scalpel,
control epithelial cells had proliferated to completely cover the
wounded areas. As the concentration of bevacizumab in-
creased, covering of corneal epithelial cells was increasingly
delayed, and at bevacizumab concentrations of 2.5 and 5 mg/
FIGURE 5. Expression of cell surface integrins of the  and  groups, and collagen types I and IV in corneal epithelial cells. Surface expression
levels of integrins 1, 2, 3, 5, v, 1, 2, and 4 and of type IV collagen significantly decreased after application of bevacizumab. *Statistically
significant differences between groups (Mann–Whitney U test).
FIGURE 4. Corneal fibroblast cells growing and Ki-67 expression after wounding with a small scalpel. (A) Twenty-four hours after wounding,
control cells had covered most of the wounded area. As the concentration of bevacizumab increased, the proliferation of corneal fibroblast cells
was progressively delayed until 24 hours after injury. (B) The expression of Ki-67 positive cells was decreased with increasing bevacizumab
concentrations. (C) The distance between the leading edge of the growing cell was measured by Image J 1.31v software. Statistically significant
differences were observed in the bevacizumab-treated groups. Student-Newman-Keuls test was used for all pairwise comparisons.
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mL, proliferation did not commence until 24 hours after injury
(Fig. 3A). The number of Ki67 positive cells reduced concen-
tration of bevacizumab dependent manner (Fig. 3B).
Corneal fibroblasts growing under 2.5 and 5 mg/mL bevaci-
zumab were just beginning to proliferate 24 hours after wound-
ing (Fig. 4A). Also, expression of Ki67 was decreased in the
same group (Fig. 4A).
Expression of Cell Surface Integrins  and 
Groups, and Expression of Collagen Types I
and IV
Surface expression of integrins 1, 2, 3, 5, 1, 2, and 4
and collagen types I and IV in corneal epithelial cells signifi-
cantly decreased in the presence of bevacizumab (Fig. 5). With
corneal fibroblast cells, similar results were seen, except that
expression of collagen IV was minimal even before exposure
to bevacizumab (Fig. 6).
Expression of Integrin 2, 3, 5, 1, and
2 mRNA
We evaluated the expression of mRNA encoding integrins 2,
3, 5, 1, and 2 in corneal epithelial and fibroblast cells. In
corneal epithelial cells, the expression levels of integrin 3 and
5 mRNA significantly decreased in the presence of bevaci-
zumab (Fig. 7). However, in corneal fibroblast cells, the ex-
pression of mRNA encoding integrins 2, 3, 5, 1, and 2 all
significantly decreased in the presence of bevacizumab (Fig. 8).
Decreases in the expression levels of various integrin mRNAs
correlated with cell surface expression of integrins in corneal
fibroblast cells. However, levels of mRNAs encoding integrin
2, 1, and 2 in corneal epithelial cells were not affected by
bevacizumab, even though the drug decreased surface expres-
sion of these proteins (see above).
DISCUSSION
Integrity and transparency of the corneal epithelium are critical
to vision. For maintenance of corneal epithelial integrity and
clarity, a good understanding of the corneal wound healing
process and NV is necessary. The biological effects of VEGF are
mediated by at least two tyrosine kinase receptors, VEGF re-
ceptors (VEGFR), VEGFR-1 and VEGFR-2.19 The blockade of
VEGFR-1 significantly suppressed VEGF-induced corneal in-
flammation20 and strong upregulation of VEGFR-2 was re-
ported during corneal NV under ischemic as well as inflamma-
tory conditions.9,21 After injury, a combination of rapid signal
transduction events and cell migration are essential for wound
healing.22 Such cell migration involves epithelial proliferation,
cell migration, cell stratification, and stromal wound healing.23
Several cytokines and other factors are involved in the regula-
tion of this cascade and many of these materials also function
to regulate NV.24 Therefore, it is not possible to view corneal
wound healing and NV as separate events.
Several studies on the safety profile of bevacizumab in
corneal cells have been published.25–27 Using in vitro assays, it
has been reported that bevacizumab was not toxic to corneal
cells of human origin at doses usually used for corneal NV
treatment.9,22 These studies used MTT assays and immunohis-
tochemistry to evaluate cell viability and cytotoxicity. The
same researchers reported that five applications of bevaci-
zumab (25 mg/mL) eyedrops in a cornea chemically burnt with
NaOH had clear anti-angiogenic effects, anti-fibrotic activity,
and maintained corneal transparency without specific tox-
icity.23
We have clearly demonstrated that bevacizumab inhibits
new corneal NV in humane corneas,18 and have also reported
significant inhibition by bevacizumab of corneal NV in a rabbit
suture model.28 However, during both animal experiments,
and when caring for our patients, we have experienced de-
FIGURE 6. Expression of cell surface integrins of the  and  groups, and collagen types I and IV in corneal fibroblast cells. The expression levels
of integrins 2, 3, 4, 5, 1, and 2, and of type I collagen significantly decreased after exposure to bevacizumab. Expression of type IV collagen
was minimal even before exposure to bevacizumab. *Statistically significant difference between groups (Mann–Whitney U tests).
FIGURE 7. RT-PCR analysis of inte-
grin 2, 3, 5, 1, and 2 expres-
sion in corneal epithelial cells. The
expression of mRNAs encoding inte-
grins 3 and 5 significantly de-
creased after bevacizumab applica-
tion. The data are mean ratio of
expression of integrin and actin 
SD; *Statistically significant differ-
ences between control and each con-
centration group (Mann–Whitney U
test).
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layed corneal epithelial healing, spontaneous epitheliopathy,
and stromal thinning.
During the rabbit corneal epithelial healing study, we ob-
served a clear bevacizumab-caused delay in corneal epithelial
wound healing after debridement. The epithelium healed com-
pletely by day 3 in control corneas, or in those receiving
bevacizumab at 0.5 mg/mL. In the 1.5, 2.5, or 5.0 mg/mL
bevacizumab-treated groups, corneal epithelium did not heal
completely by day 4 and spontaneous epithelial defects were
seen during the prolonged healing period, compromising epi-
thelial adhesion to the corneal stroma. To simulate the animal
study, we used cellular proliferation assays (using corneal ep-
ithelial and fibroblast cells) after scrape injury. By 24 hours,
control cultures of both cell types completely covered the gaps
induced by scraping, but covering of the wounded area was
delayed and the number of Ki-67 positive cells was decreased
by bevacizumab in a concentration-dependent manner. To
determine which adhesion molecules might be affected by
bevacizumab application, we performed ELISA assays to iden-
tify cell surface integrins of groups  and  and collagen types
I and IV. The expression of all these factors, in both corneal
epithelial and fibroblast cells, was decreased by application of
bevacizumab. Corneal wound healing was related to expres-
sion of adhesion molecules. Integrins are well-known mole-
cules of this type that bridge the cell to many components of
the extracellular matrix (ECM), such as laminins and collagens,
and thereby transduce intracellular signals that alter numerous
cell properties such as adhesion, migration, proliferation, and
survival.29 Integrin 51 is the classic fibronectin receptor,
and when expressed with additional integrins that bind to
fibronectin, mediates cellular attachment to the ECM.30
VEGFR-1, which contains the binding determinants for VEGF,
is involved in the interaction with 51 integrin.31 The essen-
tial role of integrin 51 in the cornea as a regulator of corneal
NV was suggested.32 Exposure to culture medium containing
1.5 mg/mL bevacizumab reduced expression of surface inte-
grins and collagens. This means that bevacizumab might inhibit
not only corneal NV, but also the adhesion of corneal cells, and
other integrin-related events.
When RT-PCR was used to evaluate the effect of bevaci-
zumab on the synthesis of integrin mRNAs in corneal cells,
there were differences in the expression of relevant mRNAs
between corneal epithelial and fibroblast cells. RT-PCR of
mRNA from corneal fibroblast cells showed that the expression
levels of mRNAs encoding all integrins 2, 3, 5, 1, and 2
decreased. However, in corneal epithelial cells, inhibition of
mRNAs encoding only integrin 3 and 5 was seen. Integrin
surface expression on corneal epithelial cells was affected by
bevacizumab, but the mRNA expression was not affected at
levels of 1.5 mg/mL.
NV is the result of a complex interplay among pro-angio-
genic factors, cell adhesion, and matrix remodeling.33 Blocking
of integrin 11 reduces inflammation-induced tissue response
and promotes cornea allograft survival,34 and integrin 5 in-
hibiting small molecules blocks the outgrowth of new lym-
phatic vessel into the cornea.35 Induction of angiogenesis by
VEGF is associated with selective upregulation of integrin 
v5.
36 Other members of the integrin family implicated in
mediating the angiogenic response include 11, 21, and
51, and these have also been shown to be involved in
VEGF-associated angiogenic events.37,38
Therefore, modulation of corneal NV by blocking VEGF
function also influences corneal physiology, especially devel-
opment of the inflammatory state, which is expected to con-
tribute to the wound healing process.
Previous reports have focused on cell viability assays to
evaluate corneal safety of bevacizumab. In this study, we mea-
sured the effect of bevacizumab on the rate of epithelial wound
healing, cell proliferation, and expression of integrins. We
found that bevacizumab delayed corneal wound healing and
inhibited integrin expression. These data explained our earlier
findings of corneal epitheliopathy after application of bevaci-
zumab-containing topical eyedrops, even though corneal new
vessel development was successfully inhibited.
When considering the use of bevacizumab to reduce cor-
neal new vessel development, physicians should remember
that the drug might delay wound healing and should be cau-
tious in applying bevacizumab under active inflammatory con-
ditions.
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